LUND, Sweden, April 12, 2021 /PRNewswire/ -- BioInvent
International AB ("BioInvent") (Nasdaq Stockholm: BINV) today
announced that Oncurious NV has presented data from a phase I dose
escalation study of TB-403 in pediatric subjects with relapsed or
refractory medulloblastoma (MB) at the annual meeting of the
American Association for Cancer Research (AACR).
The conclusion from the phase I study is that the results
warrant further evaluation of TB-403 in pediatric subjects with
relapsed or refractory medulloblastoma (MB). TB-403 has an Orphan
Designation for medulloblastoma from the European Medicines Agency
(EMA). For further information and the complete press release,
please visit https://www.oncurious.com/news-events/latest-news.
TB-403 is an anti-PIGF (anti-placenta growth factor) antibody
and it is currently in development by Oncurious NV, a subsidiary of
Oxurion NV. TB-403 was formerly jointly developed by BioInvent and
Oncurious but is, as previously informed, no longer one of
BioInvent's focus projects. BioInvent has no further development
costs for the project but has retained rights to 50 percent of
future revenues after the deduction of some of the past, and all of
the future, development costs related to TB-403.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a
clinical-stage biotech company that discovers and develops novel
and first-in-class immuno-modulatory antibodies for cancer therapy,
with currently three drug candidates in four ongoing clinical
programs in Phase l/ll trials for the treatment of hematological
cancer and solid tumors, respectively. The Company's validated,
proprietary F.I.R.S.T™ technology platform simultaneously
identifies both targets and the antibodies that bind to them,
generating many promising new drug candidates to fuel the Company's
own clinical development pipeline or for additional licensing and
partnering.
The Company generates revenues from research collaborations and
license agreements with multiple top-tier pharmaceutical companies,
as well as from producing antibodies for third parties in the
Company's fully integrated manufacturing unit. More information is
available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor
Relations
+46 (0)46 286 85
50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
The information was submitted for publication at 07:30 a.m. CEST on April
12, 2021.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bioinvent-international-ab/r/bioinvent-s-partner-oncurious-nv-presents-phase-i-data-on-tb-403-in-pediatric-cancer,c3323127
The following files are available for download:
https://mb.cision.com/Main/583/3323127/1399781.pdf
|
BioInvent’s partner
Oncurious NV presents Phase I data on TB-403 in pediatric
cancer
|